Cardio Diagnostics Holdings (CDIO) Cash & Equivalents (2021 - 2026)

Cardio Diagnostics Holdings has reported Cash & Equivalents for 6 years, with the latest figure at $7.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 26.96% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (down 26.96% YoY) and the FY2025 annual result came in at $5.1 million, down 34.71% from the prior year.
• Cash & Equivalents climbed to $7.1 million in Q1 2026 per CDIO's latest filing, from $5.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $9.7 million in Q1 2025 and troughed at $250000.0 in Q3 2025.
• A 5-year average of $4.9 million and a median of $5.0 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents jumped 92493.82% in 2022, then sank 87.39% in 2025.
• Over 5 years, Cash & Equivalents stood at $4.1 million in 2022, then plunged by 68.83% to $1.3 million in 2023, then soared by 509.84% to $7.8 million in 2024, then slumped by 34.71% to $5.1 million in 2025, then surged by 38.48% to $7.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $7.1 million, $5.1 million, and $250000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.